Over the past decade, biomanufacturing has become a strategic driver to scalable and flexible operations, controlled costs, and high quality drug market access.¹  The advances in manufacturing technologies–in particular continuous manufacturing, process analytical technology, single-use systems, alternative down processing techniques and drug device systems–continue to influence the biopharmaceutical workforce, impacting the manufacturers’ collaboration strategies and their choices of facility locations.

In the upcoming BIOMANUFACTURING GLOBAL CONGRESS 2017 EUROPE, a more reactive and dynamic approach to key trends, methodologies and insights on manufacturing, supply chain, quality management and compliance than the current industry standard is anticipated.